Camp4 Therapeutics (NASDAQ:CAMP) reported quarterly losses of $(0.87) per share which missed the analyst consensus estimate of $(0.30) by 190 percent. This is a 12.99 percent decrease over losses of $(0.77) per share from the same period last year. The company reported quarterly sales of $348.000 thousand which missed the analyst consensus estimate of $538.000 thousand by 35.32 percent. This is a 46.63 percent decrease over sales of $652.000 thousand the same period last year.